About the Company

nPharmakon has invented a breakthrough technology for uncovering previously unrecognized molecular targets of existing small molecule drugs, suggesting new therapeutic uses for the drugs and their derivatives.

nPharmakon was founded in 2008, became a clinical-stage company in 2011, and demonstrated clinical proof-of-concept for its leading development candidate in 2012.

Dmitri Rebatchouk, PhD - Chief Executive Officer
Previously at CuraGen, Hoechst Marion Roussel, Aventis, sanofi-aventis.
Felix Sheinerman, PhD - Chief Scientific Officer
Previously at Columbia University, Aventis, sanofi-aventis.
Don Picker, PhD - VP Drug Development
Previously at SmithKline Beecham, Johnson Matthey, Genta, LXR Biotechnology.